National Resilience will close a number of its manufacturing sites in the U.S. as it focuses on high-growth segments to advance cell-based medicines, primarily biologics, and aseptic drug product operations. The contract development and manufacturing organization noted that the decision was taken after it became 'clear that our capacity expansion has outpaced industry demand.'
